"Suntan Drug Greenlighted for Trials"
The article cites studies showing 5 to 15 percent of GLP-1 users experience mild injection-site reactions, and calls bruising one of the most common and typically benign presentations
The addition underscores Ros strategy of positioning itself as a one-stop shop for obesity care, blending telehealth consultations, insurance navigation and pharmacy services
These aim to boost effectiveness and convenience even further, potentially changing how we approach long-term weight management
They are not approved for human or veterinary use, and are intended solely for experimental or research purposes
Al-Attar A, Presnell SR, Peterson CA, Thomas DT, Lutz CT